Risk of Midlife Stroke After Adverse Pregnancy Outcomes: The FinnGen Study

Eliza C. Miller(University of Pittsburgh), Jeffrey F. Waring(AbbVie (United States)), Jaakko Kaprio(University of Helsinki), Robert Graham(GenProMarkers (United States)), Anne Pitkäranta, Antti Hakanen, Deepak Raipal, Jukka Partanen(Finnish Red Cross), George Okafo, Dirk S. Paul(AstraZeneca (United Kingdom)), Sarah E. Tom(Columbia University), Simonne Longerich, Anders Mälarstig(Karolinska Institutet), Tarja Laitinen(Tampere University), Anni Kauko(University of Turku), Eric Green(National Institutes of Health), Chris O ́Donnell, Hannele Laivuori(University of Helsinki), Tomi P. Mäkelä(University of Helsinki), Raimo Pakkanen, Marco Hautalahti, Athena Matakidou(AstraZeneca (Sweden)), Markus Perola(Broad Institute), Jari A. Laukkanen(University of Eastern Finland), Outi Tuovila, Bridget Riley-Gills, Mark I. McCarthy(Centre for Human Genetics), Raisa Serpi, Howard J. Jacob(Medical College of Wisconsin), Terhi Kilpi(Finnish Institute for Health and Welfare), Taneli Raivio(University of Helsinki), Margaret G. Ehm(GlaxoSmithKline (United States)), Adam Platt(AstraZeneca (United Kingdom)), Teemu Niiranen(Edinburgh Napier University), Aarno Palotie(Broad Institute), Heiko Runz(Heidelberg University), Joseph Maranville(Finnish Institute for Health and Welfare), Robert M. Plenge, Mark J. Daly(Broad Institute), Caroline S. Fox(Boston University), Robert Yang, Julie Hunkapiller, Veli‐Matti Kosma(University of Eastern Finland), Sally John, Petri Virolainen, Kirsi Auro(University of Helsinki), Heli Salminen‐Mankonen, Nathan Lawless, K. Klinger(Sanofi (France)), Natalie A. Bello(Institute for Family Health)
Cited by 27


Related Papers